| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5472 | Vu6013429 | Novel PAM of Group III (mGlu4/6/7/8) mGlu receptors |
|
| DCC5473 | Vu6017587 | Novel selective mGlu3 NAM, showing efficacy in tail suspension, elevating zero maze and marble burying, suggesting selective inhibition of mGlu3 affords anxiolytic-like and antidepressant-like phenotypes in mice |
|
| DCC5474 | Vu6027459 | First-in-class selective mGlu7 positive allosteric modulator (PAM), displaying CNS penetration in both mice (Kp = 2.74) and rats (Kp= 4.78) |
|
| DCC5475 | Vuf 5681 Dihydrobromide | Potent histamine H3 receptor silent antagonist |
|
| DCC5476 | Vuf10132 | Novel full inverse agonist at CXCR3 N3.35A |
|
| DCC5477 | vuf10148 | Potent H4R ligand |
|
| DCC5478 | Vuf10166 Hydrochloride | Novel potent ligand at 5-HT3A and 5-HT3AB receptors with different activities |
|
| DCC5479 | Vuf10497 Featured | VUF10497 is a potent histamine H4 receptor (H4R) inverse agonist with anti-inflammatory activity. |
|
| DCC5480 | Vuf10499 | Potent human H4 receptor inverse agonist |
|
| DCC5481 | Vuf10558 | Highly Potent Human Histamine H4 Receptor Inverse Agonist |
|
| DCC5482 | Vuf11211 | Potent CXCR3 Antagonist, extending from the minor pocket into the major pocket of the transmembrane domains and binding between residues in helices 1 (Y1.39), 2 (W2.60), 3 (F3.32), 4 (D4.60), 6 (Y6.51), and 7 (S7.39, Y7.43) |
|
| DCC5483 | Vuf11222 | First reported nonpeptidomimetic agonist on The G protein-coupled chemokine receptor CXCR3 |
|
| DCC5484 | vuf14480 | Partial agonist in hH 4 R-mediated G protein signalling and β-arrestin2 recruitment, bounding covalently to the hH4R |
|
| DCC5485 | Vuf14738 | Novel robust and fatigue-resistant photoswitchable GPCR antagonist |
|
| DCC5486 | Vuf14862 | Novel robust and fatigue-resistant photoswitchable GPCR antagonist |
|
| DCC5487 | Vuf15259 | Novel inhibitor of Hbp secretion, activating σE stress, impairing Hbp secretion and decreasing the abundance of OMPs, consistent with impaired BAM function |
|
| DCC5488 | Vuf15888 | Novel photoswitchable modulator of the CXCR3 chemokine receptor |
|
| DCC5489 | Vuf16216 | Novel CXCR3 ligand, photoswitching from antagonism to agonism |
|
| DCC5490 | Vuf16620 | Novel photoswitchable modulator of the CXCR3 chemokine receptor |
|
| DCC5491 | vuf5228 | Histamine H3 receptor antagonist |
|
| DCC5492 | Vuf5391 | H3R inverse agonist |
|
| DCC5493 | vuf5455 | Adenosine A3 receptor (A3AR) allosteric modulator |
|
| DCC5494 | Vuf5834 | Novel full inverse agonist at CXCR3 N3.35A |
|
| DCC5495 | Vuf-6884 | Full agonist of hH4R with ~300-fold selectivity over hH3R and hH2R, but showing potent inverse agonistic activity at hH1R |
|
| DCC5496 | Vuf-8430 | Potent histamine H4 receptor full agonist |
|
| DCC5497 | Vuf8504 | Allosteric modulator of A3 adenosine receptors |
|
| DCC5498 | Biricodar(Vx-710) Featured | Biricodar (VX-710) is a multidrug resistance (MDR) modulator that targets two key drug efflux transporters: P-glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP-1). These transporters are often overexpressed in cancer cells and contribute to multidrug resistance (MDR) by pumping chemotherapeutic drugs out of the cells, reducing their intracellular concentration and efficacy. Biricodar inhibits the function of Pgp and MRP-1, effectively chemosensitizing multidrug-resistant cancer cells and enhancing the effectiveness of chemotherapy agents. Its ability to reverse MDR makes it a promising candidate for improving cancer treatment outcomes. |
|
| DCC5499 | Vzmc013 | Novel Probe of Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity |
|
| DCC5500 | w-13 Hydrochloride Featured | W-13 hydrochloride is a calmodulin antagonist. W-13 hydrochloride can inhibit Tamoxifen (HY-13757A)-resistant human breast cancer cell growth. |
|
| DCC5501 | w-5 Hydrochloride | Calmodulin antagonist, inhibiting Ca2+/calmodulin-regulated enzyme activities |
|
